JPH01301624A - Anti-adhesion material - Google Patents
Anti-adhesion materialInfo
- Publication number
- JPH01301624A JPH01301624A JP13170788A JP13170788A JPH01301624A JP H01301624 A JPH01301624 A JP H01301624A JP 13170788 A JP13170788 A JP 13170788A JP 13170788 A JP13170788 A JP 13170788A JP H01301624 A JPH01301624 A JP H01301624A
- Authority
- JP
- Japan
- Prior art keywords
- water
- formula
- adhesion
- groups
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は生体組織の癒着防止材に関し、さらに詳しくは
、外科手術後に起る癒着の発生を防止するだめの材料に
関する。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a material for preventing adhesion of living tissues, and more particularly to a material for preventing the occurrence of adhesions after surgical operations.
(従来の技術)
外科手術後の癒着は古くから関心がもたれてきているが
、いまだに満足すべき防止方法はない。(Prior Art) Adhesions after surgery have been of interest for a long time, but there is still no satisfactory prevention method.
とくに開腹術後には腹腔内臓器間あるいは臓器と腹壁と
の癒着がしばしば起り、小腸、大腸のイレウス(腸閉塞
症)、内臓器障害等の原因となり、大きな問題となって
いる。Particularly after laparotomy, adhesions between intra-abdominal organs or between organs and the abdominal wall often occur, causing ileus (intestinal obstruction) in the small intestine or large intestine, internal organ damage, etc., and are a major problem.
従来、線維素溶解物質、膜様物質、油剤等が癒着防止の
ために試験されてきたが、操作が簡単で効果の確実な手
段は未だに見出されていない。最近の例でも、酸化再生
セルロースの織物(特開昭62−47364) 、ヒア
ルロン酸塩ゲルフィルム(特開昭61−502729
)等の膜様物質を用いる方法が提案されているが、これ
らは創面を物理的に被覆しようとするものであり、例え
ば腹腔内における腸管癒着のような広範囲での癒着を防
止するには不適当である。Hitherto, fibrinolytic substances, membranous substances, oil agents, and the like have been tested to prevent adhesions, but an easy-to-use and reliable means has not yet been found. Recent examples include oxidized regenerated cellulose fabric (Japanese Patent Application Laid-open No. 62-47364) and hyaluronate gel film (Japanese Patent Application Laid-open No. 61-502729).
) have been proposed, but these methods attempt to physically cover the wound surface and are not suitable for preventing widespread adhesions such as intestinal adhesions within the abdominal cavity. Appropriate.
また、特開昭57−167919にはアルギン酸ナトリ
ウム水溶液を使用する方法が開示されている。この技術
には膜様物質の使用に伴なう上記欠点はないが、■非常
に高濃度の溶液を必要とすること、■海藻よりの抽出物
であり構成成分であるD−マンヌロン酸とL−ブロクロ
ン酸の組成・配列は原料により異なっていて一定のもの
を得るのは難しいごと、■アルギン酸すl・リウムはカ
ルシウムイオン等の2価以上の金属イオンと結合して不
溶化し析出する性質をもっており、体内に多量のアルギ
ン酸すトリウムを導入することにより体内の金属イオン
のバランスを崩す恐れがある等の欠点がある。Further, Japanese Patent Application Laid-Open No. 57-167919 discloses a method using an aqueous sodium alginate solution. This technique does not have the above-mentioned drawbacks associated with the use of membrane-like materials, but it requires (1) a very highly concentrated solution; (2) it is an extract from seaweed and is composed of D-mannuronic acid and L. -The composition and arrangement of brocuronic acid differs depending on the raw material, and it is difficult to obtain a constant one. ■Alginate sulfur and lithium have the property of binding with divalent or higher valent metal ions such as calcium ions, making them insoluble and precipitating. However, there are drawbacks such as the risk of disrupting the balance of metal ions in the body by introducing a large amount of thorium alginate into the body.
(発明が解決しようとする課題)
」−記のような従来技術における問題点の存在に鑑み、
本発明においては、簡単な操作で広範囲にわたって癒着
の発生を確実に防止することができ、しかも生体機能に
悪影響を及ばずことのない癒着防止効果を提供しようと
するものである。(Problem to be solved by the invention) - In view of the existence of problems in the prior art as described below,
The present invention aims to provide an adhesion-preventing effect that can reliably prevent the occurrence of adhesions over a wide range with simple operations and does not adversely affect biological functions.
(課題を解決するだめの手段)
本発明者らは、かかる本発明の目的を達成するために鋭
意研究を行なった結果、水溶性のセルロース誘導体を主
成分とする組成物を用いることにより簡単な操作により
効果的に癒着を防止できることを見出し、この知見に基
づいて本発明を完成するに到った。(Another Means to Solve the Problems) As a result of intensive research to achieve the object of the present invention, the present inventors have found that a simple solution can be achieved by using a composition containing a water-soluble cellulose derivative as a main component. It was discovered that adhesions can be effectively prevented by manipulation, and the present invention was completed based on this knowledge.
すなわち、かかる本発明は、−i式
(式中、Rは水素原子、アルキル基、およびヒドロキシ
アルキル基、カルボキシアルキル基。That is, the present invention provides a formula -i (wherein R is a hydrogen atom, an alkyl group, a hydroxyalkyl group, or a carboxyalkyl group).
スルホン化アルキル基、アミノアルキル基等の置換アル
キル基からなる群から選択された複数種の原子または基
を示し、それぞれのRはかかる複数種の原子または基の
いづれかをそれぞれ表わすと共に式中のRのすべてには
かかる複数種の原子または基のすべてが含まれる。)で
示される水溶性のセルロース誘導体を主成分とする癒着
防止材である。It represents a plurality of atoms or groups selected from the group consisting of substituted alkyl groups such as sulfonated alkyl groups and aminoalkyl groups, and each R represents one of the plurality of atoms or groups, and R in the formula All of the above include all such plural types of atoms or groups. ) is an anti-adhesion material whose main component is a water-soluble cellulose derivative.
本発明において用いられるセルロース誘導体は、前記の
一般式で示される水溶性のセルロース誘導体であり、そ
の具体例として、例えばメチルセルロース、ヒドロキシ
プロピルメチルセルロース、カルボキシメチルセルロー
スナトリウムなどが挙げられる。これらはその代表的な
ものを市販品として容易に入手できるが、パルプ等のセ
ルロース原料とハロゲン化(置換)アルキルとの反応を
行なうことにより、また、さらに生成物に対して通常の
化学反応を行うことにより得ることもできる。The cellulose derivative used in the present invention is a water-soluble cellulose derivative represented by the above general formula, and specific examples thereof include methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and the like. Typical of these are easily available as commercial products, but they can be produced by reacting a cellulose raw material such as pulp with a (substituted) alkyl halide, or by further subjecting the product to a normal chemical reaction. It can also be obtained by doing.
これらのセルロース誘導体は水溶性であればその置換度
に特に制限はない。本発明においてセルロース誘導体に
必要な水溶性とは、セルロース誘導体が水または生理的
食塩水と実用的配合割合で混合されたとき、生理的な温
度を中心とする上下約7度内、すなわち30〜45℃の
範囲内で自由流動性を有する均一な組成物を与えること
をいう。There is no particular restriction on the degree of substitution of these cellulose derivatives as long as they are water-soluble. In the present invention, the water solubility required for the cellulose derivative means that when the cellulose derivative is mixed with water or physiological saline at a practical mixing ratio, the water solubility is within about 7 degrees above and below the physiological temperature, that is, 30 to 30 degrees. It refers to providing a uniform composition with free-flowing properties within a temperature range of 45°C.
このような水溶性を有するセルロース誘導体として、た
とえばセルロース中の水酸基の27〜32%がメトキシ
基に置換されたメチルセルロース、セルロース中の水酸
基の19〜30%がメトキシ基にまた4〜12%がヒド
ロキシプロポキシ基に置換されたヒドロキシプロピルメ
チルセルロース、セルロース中の水酸基の16〜24%
がカルボキシメチル基のすトリウム塩に置換されたカル
ボキシメチルセルロースナトリウムなどが挙げられる。Examples of such water-soluble cellulose derivatives include methylcellulose in which 27-32% of the hydroxyl groups in cellulose are substituted with methoxy groups, and 19-30% of the hydroxyl groups in cellulose are substituted with methoxy groups, and 4-12% are hydroxyl groups. Hydroxypropyl methylcellulose substituted with propoxy groups, 16-24% of hydroxyl groups in cellulose
Examples include sodium carboxymethylcellulose in which the carboxymethyl group is substituted with a thorium salt.
各セルロース誘導体の分子量についても特に制限はない
が、癒着防止効果および癒着防止材として使用時の扱い
易さの点から、20°Cにおける1%水溶液の粘度が3
O−2000cpsの範囲内のものが好ましい。There is no particular limit to the molecular weight of each cellulose derivative, but from the viewpoint of anti-adhesion effects and ease of handling when used as an anti-adhesion material, the viscosity of a 1% aqueous solution at 20°C is 3.
Preferably, it is within the range of O-2000 cps.
本発明の癒着防止材は通常上記セルロース誘導体の水溶
液として使用され、その濃度は0.1〜5゜0%の範囲
内にあるのがよく、更に好ましい濃度範囲は0.5〜3
.0%である。また、この水溶液を調製するに当って、
溶媒として水単独を用いて差支えないが、生理的食塩水
やリンケル液等に用いられる塩類等の物質を添加するこ
とができ、また生理的食塩水、リンゲル液等の溶液をそ
のまま利用することもできる。しかしながら本発明の癒
着防止材は、前述のような水溶液に限定されるものでは
なく、たとえば」−記のセルロース誘導体をマイクロカ
プセルに封入したうえ水や生理食塩水等に懸濁させたも
の、あるいはペースト状ないしはクリーム状としたもの
などであってもよい。かかる水溶液以外の剤型であると
きは、適用時において水または生理食塩水、リンゲル液
などを併用し、体腔内において最終的に上記の濃度範囲
内の水溶液となるようにすればよい。The anti-adhesion material of the present invention is usually used as an aqueous solution of the above-mentioned cellulose derivative, and its concentration is preferably within the range of 0.1 to 5%, more preferably 0.5 to 3%.
.. It is 0%. In addition, in preparing this aqueous solution,
Water alone can be used as a solvent, but substances such as salts used in physiological saline and Ringer's solution can be added, and solutions such as physiological saline and Ringer's solution can also be used as they are. . However, the anti-adhesion material of the present invention is not limited to the above-mentioned aqueous solution, but may include, for example, a cellulose derivative encapsulated in microcapsules and suspended in water or physiological saline, or It may be in the form of a paste or cream. When the dosage form is other than such an aqueous solution, water, physiological saline, Ringer's solution, etc. may be used in combination at the time of application, so that the final aqueous solution within the above concentration range is obtained in the body cavity.
さらに、本発明癒着防止材は1J11常の方法により滅
菌することができる。Furthermore, the anti-adhesion material of the present invention can be sterilized by a conventional method.
本発明の癒着防止材は、腹腔的癒着防止に用いる際には
開腹手術後の開腹部位に」−配水溶液を該部位全般に均
一にゆきわたるように注入される。When the anti-adhesion material of the present invention is used to prevent abdominal adhesions, it is injected into the abdominal region after laparotomy so that the water distribution solution is uniformly distributed throughout the area.
その適用量は開腹部位およびその面積に応して決定すれ
ばよく、開腹部位全般にゆきわたるかぎり限定されない
。通常の開腹手術の場合好ましくは20500mff、
さらに好ましくは50−350−3O0範囲とすること
ができる。The amount to be applied may be determined depending on the abdominal incision site and its area, and is not limited as long as it is applied to all abdominal incision sites. For normal open surgery, preferably 20,500 mff,
More preferably, the range is 50-350-3O0.
以下、実施例を挙げて本発明をさらムこ具体的に説明す
る。Hereinafter, the present invention will be specifically explained with reference to Examples.
跋ヰV−に)す1児升と
メチルセルロース(信越化学工業■製、メトロース5M
−4,00)を蒸留水中に熔解して、1%水溶液を調製
した。1 liter (1 liter) and methylcellulose (manufactured by Shin-Etsu Chemical Co., Ltd., Metrose 5M)
-4,00) was dissolved in distilled water to prepare a 1% aqueous solution.
パ十しLL本溌」1D−
メチルセルロース(信越化学工業flll製、メトロー
ス5lvl−1500)を蒸留水中に溶解して、2%水
溶液を調製した。A 2% aqueous solution was prepared by dissolving 1D-methylcellulose (Metrose 5lvl-1500, manufactured by Shin-Etsu Chemical Co., Ltd.) in distilled water.
パ十LL工本溌をJLL
カルボ;トシメチルセルロースナトリウム(日本合成化
学工業01製、HH)を蒸留水中に溶解して、1%水溶
液を調製した。Tosimethyl cellulose sodium (manufactured by Nippon Gosei Kagaku Kogyo 01, HH) was dissolved in distilled water to prepare a 1% aqueous solution.
試料(]オ溌思虜月
カルボキシメチルセルロースナトリウム合成化学工業(
株製、4.H)を蒸留水中に溶解して、1%水?容?夜
を調製した。Sample () Sodium Carboxymethyl Cellulose Synthetic Chemical Industry (
Co., Ltd., 4. Dissolve H) in distilled water to make 1% water? Yong? Prepared the night.
抜柱−L」目幻硼し
アルギン酸ナトリウム(君津化学工業+Tり製、■−3
F)を蒸留水中に熔解して、1%水溶液を調製した。Extracting pillar-L” Sodium alginate (manufactured by Kimitsu Chemical Industry +T, ■-3
F) was dissolved in distilled water to prepare a 1% aqueous solution.
評誦試襞
6週令のウィスターラソl− (オス)に対して、次の
ようにして盲腸部に癒着を発生させる処置を行ない、そ
の際に適用した癒着防止材の効果を調べた。すなわち、
(]) エエールにより眠らせたのちケクラールを筋
注して麻酔する。Evaluation test A 6-week-old Wistar Lasso l- (male) was treated as follows to generate adhesions in the cecal region, and the effect of the anti-adhesion material applied at that time was investigated. That is, (]) After the patient is put to sleep with air, Keklar is injected intramuscularly to anesthetize the patient.
(2)電気バリカンを用いて腹部を毛剃りする。(2) Shave the abdomen using electric clippers.
(3) ヒビテンを用いて腹部を消毒する。(3) Disinfect the abdomen using Hibitene.
(4)開腹して盲腸部を引き出す。(4) Open the abdomen and pull out the cecum.
(5)盲腸部をガーゼでこずり、盲腸部の紫膜を約半周
にわたり剥離する。(5) Rub the cecum with gauze and peel off the purple membrane around half the circumference of the cecum.
(6) それぞれ癒着防止材の試料l mRを、腹腔
内に注入する。(6) Inject 1 mR of each sample of anti-adhesion material into the abdominal cavity.
(7)切開部の内側を絹糸で縫合し、さらに皮膚をホチ
キス針No. 1. 0で閉しる。(7) The inside of the incision was sutured with silk thread, and the skin was then closed with staple No. 1. Close with 0.
(8)4週間飼育後、再度開腹し癒着発生の有無を調べ
る。(8) After 4 weeks of rearing, the abdomen is opened again and the presence or absence of adhesions is examined.
このようにして評価した結果を、(癒着のあったラット
の頭数/評価したラットの頭数)の数値により癒着数と
して第1表に示した。The results of the evaluation in this way are shown in Table 1 as the number of adhesions based on the numerical value of (number of rats with adhesions/number of rats evaluated).
なお、本発明の癒着防止材の適用による副作用は全くみ
られなかった。Incidentally, no side effects were observed at all due to the application of the anti-adhesion material of the present invention.
第 1 表
試験隔 癒着防止材 癒着数
1″ 使用せず 6/7
2 試料]1/4
3 試料2 1/6
4 試料3 1/6
5 試料4 1/6
6″″ 試料5 4/7
*・対照例
〔発明の効果〕
本発明の癒着防止材は、工業的に品質の管理されたセル
ロース誘導体を使用するもので、優れた癒着防止効果を
示すばかりでなく、使用し易くまた副作用等の少ないも
のである。Table 1 Test interval Anti-adhesion material Number of adhesion 1" Not used 6/7 2 samples] 1/4 3 Sample 2 1/6 4 Sample 3 1/6 5 Sample 4 1/6 6"" Sample 5 4/7 *・Comparative Example [Effect of the Invention] The anti-adhesion material of the present invention uses an industrially quality-controlled cellulose derivative, and not only exhibits an excellent adhesion-preventing effect, but is also easy to use and has no side effects. It is something with few.
特許出願人 日木ゼオン株式会社Patent applicant: Niki Zeon Co., Ltd.
Claims (1)
アルキル基、カルボキシアルキル基、スルホン化アルキ
ル基、アミノアルキル基等の置換アルキル基からなる群
から選択された複数種の原子または基を示し、それぞれ
のRはかかる複数種の原子または基のいづれかをそれぞ
れ表わすと共に式中のRのすべてにはかかる複数種の原
子または基のすべてが含まれる。) で示される水溶性のセルロース誘導体を主成分とする癒
着防止材。[Claims] General formula: ▲Mathematical formula, chemical formula, table, etc.▼ (In the formula, R is a hydrogen atom, an alkyl group, a hydroxyalkyl group, a carboxyalkyl group, a sulfonated alkyl group, an aminoalkyl group, etc. It represents multiple types of atoms or groups selected from the group consisting of substituted alkyl groups, each R represents one of the multiple types of atoms or groups, and all R's in the formula represent such multiple types of atoms or groups. An anti-adhesive material whose main component is a water-soluble cellulose derivative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13170788A JPH01301624A (en) | 1988-05-31 | 1988-05-31 | Anti-adhesion material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13170788A JPH01301624A (en) | 1988-05-31 | 1988-05-31 | Anti-adhesion material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01301624A true JPH01301624A (en) | 1989-12-05 |
Family
ID=15064323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13170788A Pending JPH01301624A (en) | 1988-05-31 | 1988-05-31 | Anti-adhesion material |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01301624A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003062057A (en) * | 2001-08-29 | 2003-03-04 | Next:Kk | Minute particles of biopolymer for homeostasis and adhesion prevention |
| WO2007015579A1 (en) | 2005-08-04 | 2007-02-08 | Teijin Limited | Cellulose derivative |
| WO2008096894A1 (en) | 2007-02-06 | 2008-08-14 | Teijin Limited | Cellulose derivative and method for production thereof |
| US7514097B1 (en) | 1999-11-09 | 2009-04-07 | Denki Kagaku Kogyo Kabushiki Kaisha | Use of soluble cellulose derivative having been made hardly soluble in water and process for producing the same |
| WO2010016611A1 (en) * | 2008-08-05 | 2010-02-11 | 帝人株式会社 | Hydrogel |
| WO2011121858A1 (en) | 2010-03-31 | 2011-10-06 | 株式会社ホギメディカル | Adhesion-preventing material |
-
1988
- 1988-05-31 JP JP13170788A patent/JPH01301624A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514097B1 (en) | 1999-11-09 | 2009-04-07 | Denki Kagaku Kogyo Kabushiki Kaisha | Use of soluble cellulose derivative having been made hardly soluble in water and process for producing the same |
| JP2003062057A (en) * | 2001-08-29 | 2003-03-04 | Next:Kk | Minute particles of biopolymer for homeostasis and adhesion prevention |
| WO2007015579A1 (en) | 2005-08-04 | 2007-02-08 | Teijin Limited | Cellulose derivative |
| US8378091B2 (en) | 2005-08-04 | 2013-02-19 | Teijin Limited | Cellulose derivative |
| WO2008096894A1 (en) | 2007-02-06 | 2008-08-14 | Teijin Limited | Cellulose derivative and method for production thereof |
| JP5059787B2 (en) * | 2007-02-06 | 2012-10-31 | 帝人株式会社 | Cellulose derivative and method for producing the same |
| US8455001B2 (en) | 2007-02-06 | 2013-06-04 | Teijin Limited | Cellulose derivative and method for production thereof |
| WO2010016611A1 (en) * | 2008-08-05 | 2010-02-11 | 帝人株式会社 | Hydrogel |
| JP5469065B2 (en) * | 2008-08-05 | 2014-04-09 | 帝人株式会社 | Hydrogel |
| WO2011121858A1 (en) | 2010-03-31 | 2011-10-06 | 株式会社ホギメディカル | Adhesion-preventing material |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiang et al. | A cuttlefish ink nanoparticle-reinforced biopolymer hydrogel with robust adhesive and immunomodulatory features for treating oral ulcers in diabetes | |
| DE69838614T2 (en) | Carboxypolysaccharide polyether complex compositions for use in relieving surgical adhesions | |
| DE69738462T2 (en) | Bioresorbable medical devices of oxidized polysaccharides | |
| WO2020226587A1 (en) | A biocompatible, biodegradable and bioresorbable adhesion membrane including hyaluronic acid / chitosan / carboxymethyl cellulose and production method | |
| US20030073663A1 (en) | Bioabsorbable medical devices from oxidized polysaccharides | |
| JP2003192597A (en) | Adhesion preventive agent | |
| US3765419A (en) | Amylose acetate | |
| JP2003523237A (en) | Single phase gel for adhesion prevention | |
| DE2631908A1 (en) | NETWORKED POLYMER | |
| CN102604141A (en) | Method for preparing antibacterial film of quaternarized chitosan iodine complex | |
| WO2015099083A1 (en) | Aqueous dispersion for solidifying serum and blood | |
| JP2023096193A (en) | Dispersion liquid and its manufacturing method | |
| CN113577014A (en) | Medical apparatus and instrument, hydrogel and preparation method and application thereof | |
| JP2752782B2 (en) | Soluble hemostatic fabric | |
| JPH01301624A (en) | Anti-adhesion material | |
| Chiu et al. | Enhancement of antibacterial activity in electrospun fibrous membranes based on quaternized chitosan with caffeic acid and berberine chloride for wound dressing applications | |
| Wang et al. | Biomimetic poly (thioctic acid)-based bioadhesive hydrogels for wet adhesion, expeditious hemostasis and enhanced wound healing | |
| JP2003523459A (en) | Chitosan condensation products, their production and use | |
| RO131947A2 (en) | Stabilized solution based on active ingredients and method for preparing the stabilized solution of active ingredients | |
| JPS648603B2 (en) | ||
| JP3560916B2 (en) | Methods and compositions for preventing postoperative adhesion and tissue damage in surgical procedures using fluorinated polymers | |
| JP3545790B2 (en) | Intraperitoneal adhesion inhibitor | |
| JPH05331053A (en) | Solution for peritoneal lavage | |
| JP2015228969A (en) | Medical sheet material and production method of medical sheet material | |
| CN103893834A (en) | Application of bletilla striata (Thunb.) Reichb.F. polysaccharide in postoperation anti-blocking agent |